Cardiovascular Effects of Osteoporosis Treatment

Parker J, Paskins Z, Poole K, et al.“J. UK clinical guideline for the prevention and treatment of osteoporosis”. Arch Osteoporos. 2022 Apr 5 17(1):58. ve doi:.10.1007/s11657-022-01061-5.,

Seeto AH, Tadrous M, Gebre AK et al.“Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis”. Bone. 2023 Feb ve 167:116610.

Yesil Y, Ulger Z, Halil M, et al. Coexistence of osteoporosis (OP) and coronary artery disease (CAD) in the elderly: it is not just a by chance event. Archives of Gerontology Geriatrics. 2012 54(3):473-476. doi:10.1016/j.archger.2011.06.007,

Morin SN, Feldman S, Funnell L, et al. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. CMAJ. 2023;195(39):E1333-E1348. doi:10.1503/cmaj.221647

Kanis JA, Cooper C, Rizzoli R, et al. “European guidance for the diagnosis and management of osteoporosis in postmenopausal women” Osteoporosis International. 2019 30(1):3–44. doi:10.1007/s00198-018-4704-5.

Manson JE, Cook NR, Lee IM et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019 380:33–44 DOI:.10.1056/NEJMoa1809944.,.

Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high‐dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study: a randomized clinical trial. JAMA Cardiology. 2017 2:608–616. DOI:.10.1001/jamacardio.2017.0175.,

Arora P, Song Y, Dusek J, et al. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation. 2015 131(3):254-262.doi:10.1161/CIRCULATIONAHA.114.011732,

Barbarawi M, Kheiri B, Zayed Y, et al. Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis [published correction appears in JAMA Cardiology. 2020 Jan 1;5(1):112.

Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study: a randomized clinical trial. JAMA Cardiology. 2017 2(6):608–616. doi:. 10.1001/jamacardio.2017.0175.,

Bouillon R. (2019). Vitamin D and cardiovascular disorders. Osteoporosis international: 30(11), 2167–2181. https://doi.org/10.1007/s00198-019-05098-0.

Pepe J, Cipriani C, Sonato C, et al. “Cardiovascular manifestations of primary hyperparathyroidism: a narrative review”. European Journal of Endocrinology. 2017,177(6):R297–R308.doi:. 10.1530/EJE-17-0485.,

Grübler MR, März W, Pilz S, et al. Vitamin-D concentrations, cardiovascular risk and events - a review of epidemiological evidence. Reviews in Endocrine&Metabolic Disorders. 2017,18(2):259-272. doi:10.1007/s11154-017-9417-0,

Bassuk SS, Manson JE. The Timing Hypothesis: do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolic Clinical Experiment. 201, 65(5):794–803.ve doi: 10.1016/j.metabol.2016.01.004.

Baber RJ, Panay N, Fenton A, 2016, IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 19(2):109-150. doi:10.3109/13697137.2015.1129166,

Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004,292(13):1573–1580.ve doi: 10.1001/jama.292.13.1573,

Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovascular Research. 2002 53(3):605–619 doi:10.1016/s0008-6363(01)00466-7.,.

Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine 2007,1809-1822., 356:.

Fuggle NR, Cooper C, Harvey NC, et al. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs. 2020 80(15):1537-1552. doi:10.1007/s40265-020-01364-2,

Rodríguez AJ, Ernst MT, Nybo M, et al. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density. Journal of Clinical Endocrinology&Metabolism. 2020 105(10) doi:10.1210/clinem/dgaa481.

Sing CW, Wong AY, Kiel DP, et al. Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture. Journal of Bone Mineral Research. 2018 33(8):1422-1434. doi:10.1002/jbmr.3448,

Bunch TJ, Anderson JL, May HT, et al. Relation of bisphosphonate therapies and risk of developing atrial fibrillation. The American journal of cardiology. 2009 103(6):824–828. doi:10.1016 /j.amjcard.2008.11.037.,

Herrera, L., I. Leal, F. Lapi, et al. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. Osteoporosis International 2015.26: 1499– 1506.

Erichsen, R., C.F. Christiansen, T. Frøslev, et al. Intra- venous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. British Journal of Cancer Research. 2011.105: 881–883.

Park JH, Ko HJ. The Association between Treatment with Bisphosphonates and the Risk of Atrial Fibrillation: A Meta-Analysis of Observational Studies. Korean Journal of Family Medicine. 2022 43(1):69-76. doi:10.4082/kjfm.21.0110,

Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020 142(15):e214-e233. doi:10.1161/CIR.0000000000000905,

Boyce B.F., Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives Biochemistry. Biophysics. 2008 473:139–146. doi:10.1016/j.abb.2008.03.018.,

Lv F, Cai X, Yang W, et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone. 2020 130:115121.ve doi:10.1016/j.bone.2019.115121,

Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. Journal of Bone Mineral Research. 2014;29(2):450-457. doi:10.1002/jbmr.2043

Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl Journal of Medicine. 2009 361(8):756–765. doi: 10.1056/NEJMoa0809493.

Cosman F, Cooper C, Wang Y, Mitlak B,et al. “Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study”. Osteoporos International. 2022 33(8).

Nishikawa A, Ishida T, Taketsuna M, et al. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report. Clinical Interventions in Aging. 2016 11:913–925. doi:10.2147/,

Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016 316(7):722–733. doi:10.1001/jama.2016.11136.,

Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018 391(10117):230.

Final summary minutes of the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting (January 16). Food and Drug Administration, Center for Drug Evaluation and Research. 2019.

Moe SM, Chen NX, Newman CL, et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. Journal of Bone Mineral Research. 2015 30(3):499–509. doi:10.1002/jbmr.2372.,

2019., Evenity: EPAR public assessment report. European Medicines Agency.

Cosman F, Crittenden DB, Ferrari S, et al. FRAME Study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. Journal of Bone Mineral Research. 2018 33(7):1219–1226. doi:10.1002/jbmr.3427

Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. New England Journal of Medicine. 2017,377(15):1417–1427.doi: 10.1056/NEJMoa1708322.